Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Moodys
Boehringer Ingelheim
Merck
McKinsey

Last Updated: March 31, 2020

DrugPatentWatch Database Preview

Litigation Details for Forest Laboratories LLC v. Accord Healthcare Inc. (D. Del. 2015)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Forest Laboratories LLC v. Accord Healthcare Inc. (D. Del. 2015)

Docket   Start Trial Date Filed 2015-03-27
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties ACCORD HEALTHCARE INC.; ALEMBIC GLOBAL HOLDING SA; ALEMBIC PHARMACEUTICALS INC.; ALEMBIC PHARMACEUTICALS LTD.; APOTEX CORP.; APOTEX INC.; FOREST LABORATORIES HOLDINGS LTD.; FOREST LABORATORIES LLC; INVAGEN PHARMACEUTICALS INC.; MERCK KGAA; MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG; TEVA PHARMACEUTICALS USA INC.
Patents 5,532,241; 7,834,020; 8,193,195; 8,236,804; 8,673,921
Attorneys Bindu Ann George Palapura; David Ellis Moore; Eve H. Ormerod; Jack B. Blumenfeld; Jay R. Deshmukh; John C. Phillips , Jr.; John C. Rozendaal; Karen M Cassidy; Kenneth Laurence Dorsney; Maryellen Noreika; Michael E. Joffre; Michael K. Levy; Miles J. Sweet; Nathan Newbold; Neal C. Belgam; Paul M. Richter; Pei-Ru Wey; R. Touhey Myer; Robert S. Silver; Salvatore Guerriero; Steven J. Lee Ph.D.; William O. Adams
Firms Smith, Katzenstein, & Jenkins LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Forest Laboratories LLC v. Accord Healthcare Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Forest Laboratories LLC v. Accord Healthcare Inc. (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
2016-11-21 105 .S. Patent Nos. 7,834,020 ("the '020 patent"), 8,193,195 ("the '195 patent"…that because claim 1 of U.S. Patent No. 7,834,020, claim 1 of U.S. Patent No. 8,236,804, and claims 5,… ORDER CONSTRUING THE TERMS of U.S. Patent Nos. 7,834,020, 8,193,195, 8,236,804, and 8,673,921. Signed…CONSTRUING THE TERMS OF U.S. PATENT NOS. 7,834,020, 8,193,195, 8,236,804, AND 8,673,921 …in the patent. '020 patent, col. 27 ll.42-43; '804 patent, col. 28, 1. 1; '921 patent, col. External link to document
2015-03-27 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,834,020; 8,193,195; 8,236,804… 27 March 2015 1:15-cv-00272 830 Patent None District Court, D. Delaware External link to document
2016-05-25 80 Exhibits A-B U.S. Pat. No. 5,532,241, col. 8, ‘195 patent file history …, ‘195 patent file history 1 All the patents-in-suit share the same patent specification… ‘804 patent, claim 1 ‘921 patent, claims 10, … ‘020 patent, see, e.g., col. 15, ‘804 patent, claim 1 … ’241 patent, col. 8, ll. 39-55. ‘195 patent, see, e.g., col. 15, External link to document
2016-06-22 86 admits that a prior art patent, U.S. Patent No. 5,532,241 (the “ ’241 patent”), discloses vilazodone …applicants: The closest prior art is U.S. Patent no. 5,532,241, which does not teach the claimed…other disorders. The patents-in-suit are U.S. Patent Nos. 7,834,020 (the “ ’020 patent”), 8,193,195 (the…the “ ’195 patent”), 8,236,804 (the “ ’804 patent”), and 8,673,921 (the “ ’921 patent”). While Forest … the ’020 patent, claim 1 of the ’804 patent, and claims 5, 11, and 13 of the ’921 patent, “crystalline External link to document
2016-06-22 87 U.S. Patent No. 5,532,241 (“’241 patent”), which is incorporated by reference in the patents-in- …licensee of U.S. Patent Nos. 7,834,020 (“the ’020 patent”); 8,193,195 (“the ’195 patent”); 8,236,804 (“…(“the ’804 patent”); and 8,673,921 (“the ’921 patent”) (collectively, “the patents-in-suit”), which are…Merck Patent Gesellschaft mit beschränkter Haftung (collectively, “Merck”). The patents-in-suit…including major 1 The patents-in-suit all claim priority to a June 2001 patent application. External link to document
2016-06-22 88 infringed U.S. Patent Nos. 7,834,020 (the “’020 patent”), 8,193,195 (the “’195 patent”), 8,236,804 (the…22/16 Page 2 of 18 PageID #: 768 patent”) (collectively, “patents-in-suit”), by filing Abbreviated New… not present. VII. THE PATENTS-IN-SUIT 27. The patents-in-suit describe the invention…., ‘804 patent, col. 2, l. 39 to col. 3, l. 30; col. 5, ll. 1-22. Additionally, during patent prosecution…Ltd., Forest Laboratories LLC, Merck KGaA, Merck Patent Gesellschaft mit beschrankter Haftung. (Attachments External link to document
2016-07-27 93 16 Page 13 of 27 PageID #: 1000 patent – U.S. Patent No. 5,532,241 of Bottcher et al. (“Bottcher”) –…product obtained according to U.S. Pat. No. 5,532,241.” ’921 patent 5:4-6 (emphasis added). The…drug Viibryd®. The patents-in-suit are U.S. Patent Nos. 7,834,020 (the “ ’020 patent”), 8,193,195 (the…the “ ’195 patent”), 8,236,804 (the “ ’804 patent”), and 8,673,921 (the “ ’921 patent”), which all relate…administering” ’804 patent, claim 1 ’921 patent, claims 10, 12- External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
AstraZeneca
Merck
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.